Cargando…
Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504308/ https://www.ncbi.nlm.nih.gov/pubmed/31045756 http://dx.doi.org/10.1097/MD.0000000000014595 |
_version_ | 1783416549038620672 |
---|---|
author | Lei, Qiucheng Chen, Huanwei Zheng, Huazhen Deng, Feiwen Wang, Fengjie Li, Jieyuan Hu, Jianyuan Fu, Rongdang Zhen, Zuojun |
author_facet | Lei, Qiucheng Chen, Huanwei Zheng, Huazhen Deng, Feiwen Wang, Fengjie Li, Jieyuan Hu, Jianyuan Fu, Rongdang Zhen, Zuojun |
author_sort | Lei, Qiucheng |
collection | PubMed |
description | RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before. He had a hepatitis B virus (HBV) history for 20 years without treatment. DIAGNOSIS AND INTERVENTIONS: A diagnosis of primary HCC was made based on pathological examination following right hepatectomy. Seven months after the surgery, a mass in S8 was identified and treated by ARF. Twenty days later, a right zygomatic mass was observed and the incisional biopsy revealed metastasis from HCC. Due to side effects of chemotherapy, the metastatic zygomatic mass was treated with radioactive seed implantation. Despite these interventions, there was steady increase in AFP values as well as increase in size of the zygomatic mass. Hence, the patient was started on apatinib with a dose of 500 mg/day from 1 to 28 days per cycle for a duration of 10 months. OUTCOMES: The AFP values were significantly decreased but the size of the zygomatic mass continued to increase indicating progression of disease. But the progression-free survival was more than 10 months. The patient exhibited adverse reactions which were controllable by symptomatic treatments. As of last follow-up, the patient is unwell with pain in the face, blurred vision in the right eye, dyscrasia, and exhibited difficulty in opening his mouth. LESSONS: HCC metastases to the zygomatic bone are very aggressive with a very low incidence and immunohistochemistry is useful diagnostic indicators. Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone. |
format | Online Article Text |
id | pubmed-6504308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-65043082019-05-29 Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review Lei, Qiucheng Chen, Huanwei Zheng, Huazhen Deng, Feiwen Wang, Fengjie Li, Jieyuan Hu, Jianyuan Fu, Rongdang Zhen, Zuojun Medicine (Baltimore) Research Article RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before. He had a hepatitis B virus (HBV) history for 20 years without treatment. DIAGNOSIS AND INTERVENTIONS: A diagnosis of primary HCC was made based on pathological examination following right hepatectomy. Seven months after the surgery, a mass in S8 was identified and treated by ARF. Twenty days later, a right zygomatic mass was observed and the incisional biopsy revealed metastasis from HCC. Due to side effects of chemotherapy, the metastatic zygomatic mass was treated with radioactive seed implantation. Despite these interventions, there was steady increase in AFP values as well as increase in size of the zygomatic mass. Hence, the patient was started on apatinib with a dose of 500 mg/day from 1 to 28 days per cycle for a duration of 10 months. OUTCOMES: The AFP values were significantly decreased but the size of the zygomatic mass continued to increase indicating progression of disease. But the progression-free survival was more than 10 months. The patient exhibited adverse reactions which were controllable by symptomatic treatments. As of last follow-up, the patient is unwell with pain in the face, blurred vision in the right eye, dyscrasia, and exhibited difficulty in opening his mouth. LESSONS: HCC metastases to the zygomatic bone are very aggressive with a very low incidence and immunohistochemistry is useful diagnostic indicators. Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone. Wolters Kluwer Health 2019-05-03 /pmc/articles/PMC6504308/ /pubmed/31045756 http://dx.doi.org/10.1097/MD.0000000000014595 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Lei, Qiucheng Chen, Huanwei Zheng, Huazhen Deng, Feiwen Wang, Fengjie Li, Jieyuan Hu, Jianyuan Fu, Rongdang Zhen, Zuojun Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title | Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title_full | Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title_fullStr | Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title_full_unstemmed | Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title_short | Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review |
title_sort | zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: a case report and literature review |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504308/ https://www.ncbi.nlm.nih.gov/pubmed/31045756 http://dx.doi.org/10.1097/MD.0000000000014595 |
work_keys_str_mv | AT leiqiucheng zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT chenhuanwei zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT zhenghuazhen zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT dengfeiwen zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT wangfengjie zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT lijieyuan zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT hujianyuan zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT furongdang zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview AT zhenzuojun zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview |